(18 days)
The Cirona™ DVT Prevention Therapy Foot Garment is a prescription device intended to be used preventatively to increase venous blood flow in patients at risk of deep vein thrombosis due to the associated risk factors for thrombus formation during: trauma, critical care, general medicine, general surgery, as well as neurological, orthopedic, urologic, obstetric conditions and treatments.
The Cirona™ deep vein thrombosis prevention therapy foot garment is intended to be used with Devon Cirona™ 6100 deep vein thrombosis prevention system (K130571). The Cirona™ deep vein thrombosis prevention foot garment is a pair of single patient reusable soft compression garment(s) (sleeves), that consists of a brushed nylon outer material bonded to a foam inner liner. An inflatable polyvinylchloride (PVC) pressure bladder is encapsulated in an additional foam material. The patient contact material is polyurethane foam and the extension tubing set connects to the garment on one end through quick connectors and to the pump on the other end. It is intended to be used noninvasively helps reduce the incidence of deep vein thrombosis, a potentially life threatening condition.
The FDA cleared Cirona™ 6100 system (K130571) consists of a pump, a pair of single patient reusable soft compression garment(s) (sleeves), and the extension tubing set for calf and calf-thigh. This submission is for the new Cirona DVT Foot Garment which will be used in conjunction with the Cirona 6100 system. The device will alternatively inflate the two garments and mimic the natural walking pace in order to enhance circulation. The device supplied compression provides a 60-second automatically timed cycle consisting of an approximately 12-second inflation period followed by a 48-second period of relaxation. A pressure of 40mm Hg is used for all applications. This pressurization enhances venous flow and fibrinolytic activity in order to ultimately prevent early blood clotting.
Here's a breakdown of the acceptance criteria and study information for the Cirona™ DVT Foot Garment, based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
| Test | Acceptance Criteria (Implied) | Reported Device Performance |
|---|---|---|
| Pressure Accuracy | The device accurately delivers/maintains the specified pressure of 40mmHg. | Passed. "no significant difference in the inflation, deflation and pressure hold time when used in conjunction with previously FDA cleared Devon Cirona 6100 DVT Prevention Therapy System (K130571)." |
| Cycle Time Test | The device adheres to the specified cycle time (12-second inflation, 48-second relaxation, 60-second total). | Passed. "no significant difference in the inflation, deflation and pressure hold time when used in conjunction with previously FDA cleared Devon Cirona 6100 DVT Prevention Therapy System (K130571)." |
| Alarm Function Test | Alarm functions operate correctly. | Passed. (Explicit statement of passing, but no specific details about the alarm criteria are given.) |
| Sleeve Bladder Burst Test | Sleeves maintain structural integrity at the highest pressure setting for anticipated maximum treatment time. | Passed. "all samples continued to function in the original and intended manner and structure integrity was well maintained. This indicates that the Foot Garment is safe to use." |
2. Sample Size Used for the Test Set and Data Provenance
The document provides very limited information regarding sample sizes for human subjects or specific details of the "test set" for performance evaluation. The "Sleeve Bladder Burst Test" mentions "all samples," implying a sample size greater than one for that specific bench test.
Data provenance: The tests are described as "bench and laboratory testing," suggesting an in-house, prospective testing environment rather than clinical data. No country of origin for the data is specified, but the submission is to the FDA, implying testing relevant to US regulatory standards.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Those Experts
No information is provided regarding the use of human experts or establishing ground truth in the context of the described performance testing. The performance tests appear to be objective, engineering-focused benchmarks rather than clinical evaluations requiring expert interpretation.
4. Adjudication Method for the Test Set
Not applicable. The described tests are bench tests with objective pass/fail criteria, not subjective assessments requiring adjudication.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
No. The document describes bench and laboratory performance testing against specifications, not a clinical comparative effectiveness study involving human readers or AI.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
No. The device is a physical medical device (compression garment) and does not involve an algorithm in the sense of AI. The performance testing is for the physical attributes and functionality of the device itself.
7. The Type of Ground Truth Used
The ground truth for the performance tests is based on the device's own specifications (e.g., 40mmHg pressure, 12-second inflation, structural integrity). This is a form of objective engineering specification compliance rather than expert consensus, pathology, or outcomes data.
8. The Sample Size for the Training Set
Not applicable. There is no training set mentioned or implied, as this device is not an AI/machine learning product requiring training data.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no training set.
{0}------------------------------------------------
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
JUL 0 1 2013
510(K) SUMMARY
Submitter:
Devon Medical, Inc.
Contact Person:
Ruth Wu, COO 1100 First Avenue, Suite 202 King of Prussia, PA 19406 Phone: 610.757.4103 Fax: 610.930.4035
Common Classification & Proprietary Names:
Common Names: Intermittent Pneumatic Compression Device Cirona™ DVT Foot Garment Proprietary Name:
Date Prepared:
May 20th, 2013
Classification
The classification name, 21 CFR Part and Paragraph number, product code and classification of the Cirona™ DVT Foot Garment.
| Classification Name | 21.CFR Section | Product Code | Class |
|---|---|---|---|
| Compressible LimbSleeve | 870.5800 | JOW | II |
Predicate Devices:
The Cirona Deep Vein Thrombosis Prevention Therapy Foot Garment is substantially equivalent to the following.
| Predicate Device | Manufacturer | 510(k)# |
|---|---|---|
| HEALTHCARE SERVICE AND SUPPLYPVA/ALP FOOT GARMENT | Healthcare Service andSupply | K964188 |
| Devon Cirona 6100 DVT Prevention System | Devon Medical, Inc | K130571 |
Device Description
The Cirona™ deep vein thrombosis prevention therapy foot garment is intended to be used with Devon Cirona™ 6100 deep vein thrombosis prevention system (K130571). The Cirona™ deep vein thrombosis prevention foot garment is a pair of single patient reusable soft compression garment(s) (sleeves), that consists of a brushed nylon outer material bonded to a foam inner liner. An inflatable polyvinylchloride (PVC) pressure bladder is encapsulated in an additional foam material. The patient
{1}------------------------------------------------
contact material is polyurethane foam and the extension tubing set connects to the garment on one end through quick connectors and to the pump on the other end. It is intended to be used noninvasively helps reduce the incidence of deep vein thrombosis, a potentially life threatening condition.
The FDA cleared Cirona™ 6100 system (K130571) consists of a pump, a pair of single patient reusable soft compression garment(s) (sleeves), and the extension tubing set for calf and calf-thigh. This submission is for the new Cirona DVT Foot Garment which will be used in conjunction with the Cirona 6100 system. The device will alternatively inflate the two garments and mimic the natural walking pace in order to enhance circulation. The device supplied compression provides a 60-second automatically timed cycle consisting of an approximately 12-second inflation period followed by a 48-second period of relaxation. A pressure of 40mm Hg is used for all applications. This pressurization enhances venous flow and fibrinolytic activity in order to ultimately prevent early blood clotting.
Intended Use:
The Cirona ™ DVT Prevention Therapy Foot Garment is a prescription device intended to be used preventatively to increase venous blood flow in patients at risk of deep vein thrombosis due to the associated risk factors for thrombus formation during: trauma, critical care, general surgery, as well as neurological, orthopedic, urologic, obstetric conditions and treatments.
Contraindications:
The Cirona" DVT Prevention Therapy Foot Garment should NOT be used in the following conditions:
- · Severe atherosclerosis or other ischemic vascular diseases
- · Suspected or known acute deep vein thrombosis
- · Severe congestive cardiac failure
- · Existing pulmonary edema
- · Existing pulmonary embolisms
- · Extreme deformity of the limbs
- · Any local skin or tissue condition in which the garments would interfere:
- · Gangrene
- Untreated or infected wounds
- · Recent skin graft
- Dermatitis
- · Known presence of malignancy in the legs
- · Limb infections, including cellulitis, that have not received antibiotic coverage
- · Presence of lymphangiosarcoma
Technological Characteristics:
{2}------------------------------------------------
The manufacturer believes that the technological characteristics of the Cirona™ DVT Prevention Therapy Foot Garment are substantially equivalent to those of the predicate devices. The Cirona 100 DVT Foot Prevention Therapy Garment has the same components to its predicate devices and has very similar principles of operation. The material used in the foot garment is identical to previously FDA cleared Devon Cirona garments (K130571). The device consists of an electrically generated source of compressed air; tubing to convey the pressurized air to the sleeve and, like the predicates, pressure is applied cyclically for 12 seconds inflated and 48 seconds deflated. The pressure delivered is 40mmHg.
Performance Testing
Various bench and laboratory testing were performed and they assure that the product meets its specifications. The sleeve bladder burst test was performed to ensure sleeves are structurally sound during treatment and all sleeves tested maintained structural integrity at the highest pressure setting for anticipated maximum treatment time. The device passed all the tests listed below. The manufacturer believes that the technological characteristics of the Cirona™ DVT Prevention Therapy Foot Garment are substantially equivalent to those of the predicate devices. The performance testing includes the following tests:
| of Performance T | |
|---|---|
| Test 1 | Pressure Accuracy |
| Test 2 | Cycle Time Test |
| Test 3 | Alarm Function Test |
| Test 5 | Sleeve Bladder Burst Test |
Test Conclusion: Based on the specification for the Cirona DVT Prevention Therapy Foot Garment, for which substantially equivalency is claimed, there is no significant difference in the inflation, deflation and pressure hold time when used in conjunction with previously FDA cleared Devon Cirona 6100 DVT Prevention Therapy System (K130571). At the end of the sleeve bladder burst test, all samples continued to function in the original and intended manner and structure integrity was well maintained. This indicates that the Foot Garment is safe to use.
Standards
The Cirona™ DVT Prevention Therapy Foot Garment conforms to the following standards:
ISO 14971:2007 Medical devices - Application of risk management to medical devices
ISO 10993-5:2009 Biological evaluation of medical devices, Part 5: Tests for in vitro cytotoxicity
ISO 10993-10: 2012 Biological evaluation of medical devices, Part 10: Tests for irritation and skin
5.3
{3}------------------------------------------------
sensitization
ISO 10993-12: 2007 Biological evaluation of medical devices, Part 12: Biological evaluation of medical devices, Part 12: Sample preparation and reference materials
ANSI/ASQ Z1.9-2008 American National Standard: Sampling procedures and Tables for inspection by variables for percent nonconforming
Statement of Substantial Equivalence
The Cirona™ DVT Prevention Therapy Foot Garment is substantially equivalent in technology, function, operating parameters, and intended use to predicate devices that are currently commercially available and in distribution, and does not raise any new questions of safety or effectiveness.
Conclusions
In accordance with the Federal Food, Drug and Cosmetic Act and 21 CFR Part 807 ; and based on the information provided in this pre-market notification, Devon Medical Products, believes that the Cirona™ DVT Prevention Therapy Foot Garment, is substantially equivalent to the predicate devices as described herein.
{4}------------------------------------------------
Image /page/4/Picture/0 description: The image shows the logo for the Department of Health & Human Services-USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES-USA" around the perimeter. Inside the circle is an abstract image of an eagle.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - W(%6-G609 Silver Spring, MD 20993-0002
July 1, 2013
Devon Medical Inc. c/o Mr. Mark Job 1394 25th Street NW Buffalo MN 55313
Re: K131743
Trade/Device Name: Cirona 6100 Deep Vein Thrombosis Prevention Therapy Foot Garment Regulation Number: 21 CFR 870.5800
Regulation Name: Compression Limb Sleeve
- Regulatory Class: Class II
Product Code: JOW
Dated: June 17, 2013
Received: June 18, 2013
Dear Mr. Job:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enacunent date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does-not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
{5}------------------------------------------------
Page 2 - Mr. Mark Job
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers. International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.goy/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely vours.
M.A. Hillerman
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{6}------------------------------------------------
INDICATIONS FOR USE STATEMENT
510(k) Number (if known): _ K131743
Device Name: Cirona™ 6100 Deep Vein Thrombosis Prevention Therapy Foot Garment
Indications for Use:
The Cirona™ DVT Prevention Therapy Foot Garment is a prescription device intended to be used preventatively to increase venous blood flow in patients at risk of deep vein thrombosis due to the associated risk factors for thrombus formation during: trauma, critical care, general medicine, general surgery, as well as neurological, orthopedic, urologic, obstetric conditions and treatments.
Prescription Use AND/OR (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)
M.A. Hillieme
- I
§ 870.5800 Compressible limb sleeve.
(a)
Identification. A compressible limb sleeve is a device that is used to prevent pooling of blood in a limb by inflating periodically a sleeve around the limb.(b)
Classification. Class II (performance standards).